What is RetinaLogik?
RetinaLogik operates at the intersection of ophthalmology and portable technology, developing a sophisticated vision screening platform designed to mitigate the risk of preventable vision loss. The company's core value proposition lies in its ability to transform standard mobile devices into intelligent diagnostic tools. By facilitating early detection of ocular conditions through accessible, affordable, and scalable screening protocols, RetinaLogik addresses a critical void in global preventative healthcare. Their platform is engineered to empower both patients and providers, ensuring that high-quality eye health assessments are no longer confined to specialized clinical environments but are instead available to a broader demographic, thereby enhancing long-term patient outcomes.
How much funding has RetinaLogik raised?
RetinaLogik has raised a total of $1.7M across 2 funding rounds:
Other Financing Round
$577K
Debt
$1.1M
Other Financing Round (2024): $577K with participation from Halo Behavioral Health
Debt (2025): $1.1M led by Health Canada | Santé Canada
Key Investors in RetinaLogik
Halo Behavioral Health
Halo Behavioral Health offers comprehensive, evidence-based behavioral support services tailored for individuals across all ages and developmental stages, focusing on modifying and improving behavior through Applied Behavior Analysis.
Health Canada | Santé Canada
Health Canada is the federal department responsible for helping Canadians maintain and improve their health, while respecting individual choices and circumstances.
What's next for RetinaLogik?
With the recent infusion of capital, RetinaLogik is poised to transition into a phase of rapid operational scaling and market penetration. The strategic focus will likely shift toward enhancing the algorithmic precision of their screening software and expanding their footprint within both public health and private clinical sectors. As the company matures, the integration of their technology into broader telehealth ecosystems will be essential for maintaining a competitive edge. Future growth trajectories will likely involve navigating complex regulatory landscapes and forging partnerships with healthcare providers to standardize their diagnostic platform as a primary tool for early-stage vision intervention.
See full RetinaLogik company page
